End of the road for Astellas' darexaban
This article was originally published in Scrip
Executive Summary
Astellas has decided to discontinue the development of its oral direct Factor Xa inhibitor darexaban maleate in all indications and markets, pointing to difficulties in finding development partners, rising competition and other pipeline priorities.